ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-195911 |   Technology

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Alpha-1 Antitrypsin Deficiency Treatment Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET

7.1 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Grifols, S.A.

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Takeda Pharmaceutical Company Limited

16.3 CSL Behring

16.4 Kamada Pharmaceuticals

16.5 GlaxoSmithKline Plc.

16.6 AstraZeneca

16.7 Boehringer Ingelheim GmbH

16.8 Pfizer Inc.

16.9 Teva Pharmaceutical Industries Ltd.

16.10 LFB Biomedicaments S.A.

16.11 CHIESI Farmaceutici S.p.A.

16.12 Henry Schein, Inc.

16.13 Healthy Life Pharma Private Limited.

16.14 Hovione

16.15 Switzer Life science Pvt. Ltd.

16.16 Cyndea Pharma

16.17 Anuh Pharma Ltd.

16.18 Cipla Inc.

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Treatment Type
Augmentation Therapy
  o Aralast
  o Prolastin
  o Zamaira/ Respreeza,
  o Glassia
Bronchodilator
Corticosteroids
Oxygen Therapy
Others

By Route of Administration  
Parenteral
Inhalation
Oral

By End-user
Hospitals
Specialty Clinics
Pharmacies

Companies

Grifols, S.A.
Takeda Pharmaceutical Company Limited
CSL Behring
Kamada Pharmaceuticals
GlaxoSmithKline Plc.
AstraZeneca
Boehringer Ingelheim GmbH
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
LFB Biomedicaments S.A.
CHIESI Farmaceutici S.p.A.
Henry Schein, Inc.
Healthy Life Pharma Private Limited.
Hovione
Switzer Life science Pvt. Ltd.
Cyndea Pharma
Anuh Pharma Ltd.
Cipla Inc.

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.